Newsroom
            Welcome to Orion's newsroom where you can find the latest releases and articles.
        
        
    Stock exchange releases
- 10/28/2025 Orion Group Interim Report January–September 2025
- 10/24/2025 49,164 Orion Corporation A shares converted into B shares
- 9/19/2025 80,802 Orion Corporation A shares converted into B shares
- 8/20/2025 337,000 Orion Corporation A shares converted into B shares
Press releases
- 10/23/2025 Orion and Abzena announce exclusive commercial license for Abzena’s antibody
- 10/14/2025 Orion publishes Interim Report for January–September 2025 and holds a webcast on 28 October 2025
- 9/30/2025 Orion’s phase 2 study of ODM-105 in insomnia did not meet primary goal
- 7/21/2025 Darolutamide receives EU approval in third indication for patients with advanced prostate cancer
 
					Subscribe to releases
Subscribe Orion Corporation's stock exchange and press releases to your e-mail.
							Subscribe
					 
					Orion Pharma content bank
You can find and download Orion Pharma brand assets in the content bank.
							Sign in or registrate
					Corporate Communications
- 
							  Terhi OrmioVice President, Communications; primary media contact
- 
							  
- 
							  
- 
							  
- 
							  
 
													 
													 
													 
													 
													 
													 
													 
													 
								 
								 
								 
								 
								 
								 
								 
								 
								 
								 
								 
								 
								